Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows

(2020) Patrick J. Roberts et al.   MOLECULAR CANCER THERAPEUTICS

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

(2020) Anne Y Lai et al.   Journal for ImmunoTherapy of Cancer

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

(2019) Richard Gray et al.   LANCET

Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential

(2019) Samantha A. Armstrong et al.   ADVANCES IN THERAPY

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer

(2019) Yaru Tian et al.   Journal of Hematology & Oncology

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

(2019) Julia Bohlius et al.   Journal of Oncology Practice

CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?

(2019) Shom Goel et al.   LANCET ONCOLOGY

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

(2019) Antoinette R Tan et al.   LANCET ONCOLOGY

Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

(2019) A. Pavan et al.   Journal for ImmunoTherapy of Cancer

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

(2019) J M Weiss et al.   ANNALS OF ONCOLOGY

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

(2017) Shenghui He et al.   Science Translational Medicine

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes

(2017) Gary H. Lyman   Journal of the National Comprehensive Cancer Network

Small Cell Lung Cancer

(2017) Gregory P. Kalemkerian et al.   Journal of the National Comprehensive Cancer Network

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines†

(2016) J. Klastersky et al.   ANNALS OF ONCOLOGY

Measurement and control of bias in patient reported outcomes using multidimensional item response theory

(2016) N. Maritza Dowling et al.   BMC Medical Research Methodology

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

(2016) J. E. Bisi et al.   MOLECULAR CANCER THERAPEUTICS

Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies

(2016) Yanli Li et al.   SUPPORTIVE CARE IN CANCER

A review of relative dose intensity and survival in patients with metastatic solid tumors

(2015) Laura J. Havrilesky et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Origins, genetic landscape, and emerging therapies of small cell lung cancer

(2015) Ekaterina A. Semenova et al.   GENES & DEVELOPMENT

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Thomas J. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim

(2015) H. Xu et al.   SUPPORTIVE CARE IN CANCER

Transfusions and patient burden in chemotherapy-induced anaemia in France

(2014) Patricia K. Corey-Lisle et al.   Therapeutic Advances in Medical Oncology

A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer

(2011) A. Schmittel et al.   ANNALS OF ONCOLOGY

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

(2011) Sibylle Loibl et al.   BMC CANCER

Mixtures of multiple testing procedures for gatekeeping applications in clinical trials

(2011) Alex Dmitrienko et al.   STATISTICS IN MEDICINE

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

(2009) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial

(2008) Andreas Hermes et al.   JOURNAL OF CLINICAL ONCOLOGY